- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 147514, 14 pages
The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently
Clinical Oncology Laboratory, Division of Oncology, Department of Medicine, University of Patras, Patras Medical School, 26504 Rio, Greece
Received 30 April 2013; Accepted 10 June 2013
Academic Editor: Davide Vigetti
Copyright © 2013 Dionysia Lymperatou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. L. Hertz, H. L. McLeod, and J. M. Hoskins, “Pharmacogenetics of breast cancer therapies,” Breast, vol. 18, 3, pp. S59–S63, 2009.
- M. J. Higgins and J. Baselga, “Targeted therapies for breast cancer,” Journal of Clinical Investigation, vol. 121, no. 10, pp. 3797–3803, 2011.
- J. F. R. Robertson, A. Llombart-Cussac, J. Rolski et al., “Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study,” Journal of Clinical Oncology, vol. 27, no. 27, pp. 4530–4535, 2009.
- P. Friedl and S. Alexander, “Cancer invasion and the microenvironment: plasticity and reciprocity,” Cell, vol. 147, no. 5, pp. 992–1009, 2011.
- P. Friedl and K. Wolf, “Tumour-cell invasion and migration: diversity and escape mechanisms,” Nature Reviews Cancer, vol. 3, no. 5, pp. 362–374, 2003.
- S. Schmidt and P. Friedl, “Interstitial cell migration: integrin-dependent and alternative adhesion mechanisms,” Cell and Tissue Research, vol. 339, no. 1, pp. 83–92, 2010.
- P. Friedl and D. Gilmour, “Collective cell migration in morphogenesis, regeneration and cancer,” Nature Reviews Molecular Cell Biology, vol. 10, no. 7, pp. 445–457, 2009.
- A. Jezierska and T. Motyl, “Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review,” Medical Science Monitor, vol. 15, no. 2, pp. RA32–RA40, 2009.
- Y. Sullu, G. G. Demirag, A. Yildirim, F. Karagoz, and B. Kandemir, “Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast,” Pathology Research and Practice, vol. 207, no. 12, pp. 747–753, 2011.
- H. Dang, W. Ding, D. Emerson, and C. B. Rountree, “Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics,” BMC Cancer, vol. 11, article 396, 2011.
- J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, “Epithelial-mesenchymal transitions in development and disease,” Cell, vol. 139, no. 5, pp. 871–890, 2009.
- J. P. Their, “Epithelial-mesenchymal transitions in tumor progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454, 2002.
- P. J. Kowalski, M. A. Rubin, and C. G. Kleer, “E-cadherin expression in primary carcinomas of the breast and its distant metastases,” Breast Cancer Research, vol. 5, no. 6, pp. R217–R222, 2003.
- S. K. Mitra, D. A. Hanson, and D. D. Schlaepfer, “Focal adhesion kinase: in command and control of cell motility,” Nature Reviews Molecular Cell Biology, vol. 6, no. 1, pp. 56–68, 2005.
- A. Sanchez and J. Villanueva, “PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER+ breast cancer,” Expert Review of Proteomics, vol. 7, no. 6, pp. 819–821, 2010.
- A. C. Borley, S. Hiscox, J. Gee et al., “Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells,” Breast Cancer Research, vol. 10, no. 6, article R103, 2008.
- O. K. Weinberg, D. C. Marquez-Garban, M. C. Fishbein et al., “Aromatase inhibitors in human lung cancer therapy,” Cancer Research, vol. 65, no. 24, pp. 11287–11291, 2005.
- E. Giannopoulou, K. Dimitropoulos, A. A. Argyriou, A. K. Koutras, F. Dimitrakopoulos, and H. P. Kalofonos, “An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines,” Investigational New Drugs, vol. 28, no. 5, pp. 554–560, 2010.
- K. Lundgren, B. Nordenskjöld, and G. Landberg, “Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer,” British Journal of Cancer, vol. 101, no. 10, pp. 1769–1781, 2009.
- S. Oesterreich, W. Deng, S. Jiang et al., “Estrogen-mediated down-regulation of E-cadherin in breast cancer cells,” Cancer Research, vol. 63, no. 17, pp. 5203–5208, 2003.
- I. R. Hutcheson, L. Goddard, D. Barrow et al., “Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1,” Breast Cancer Research, vol. 13, no. 2, article R29, 2011.
- S. Hiscox, W. G. Jiang, K. Obermeier et al., “Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation,” International Journal of Cancer, vol. 118, no. 2, pp. 290–301, 2006.
- R. Gopalakrishna, U. Gundimeda, J. A. Fontana, and R. Clarke, “Differential distribution of protein phosphatase 2A in human breast carcinoma cell lines and its relation to estrogen receptor status,” Cancer Letters, vol. 136, no. 2, pp. 143–151, 1999.
- X. Wu, M. Subramaniam, S. B. Grygo et al., “Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen,” Breast Cancer Research, vol. 13, no. 2, article R27, 2011.
- T. N. Mitropoulou, G. N. Tzanakakis, D. Kletsas, H. P. Kalofonos, and N. K. Karamanos, “Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells,” International Journal of Cancer, vol. 104, no. 2, pp. 155–160, 2003.
- S. H. Ngalim, A. Magenau, G. Le Saux, J. J. Gooding, and K. Gaus, “How do cells make decisions: engineering micro- and nanoenvironments for cell migration,” Journal of Oncology, vol. 2012, Article ID 363106, 2010.
- J. Sastre-Serra, M. Nadal-Serrano, D. G. Pons, A. Valle, J. Oliver, and P. Roca, “The effects of 17β-estradiol on mitochondrial biogenesis and function in breast cancer cell lines are dependent on the ERα/ERβ Ratio,” Cellular Physiology and Biochemistry, vol. 29, no. 1-2, pp. 261–268, 2012.
- S.-H. Park, L. W. T. Cheung, A. S. T. Wong, and P. C. K. Leung, “Estrogen regulates snail and slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor α,” Molecular Endocrinology, vol. 22, no. 9, pp. 2085–2098, 2008.
- O. C. Kousidou, A. Berdiaki, D. Kletsas et al., “Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells,” Molecular Oncology, vol. 2, no. 3, pp. 223–232, 2008.
- G. Cory, “Scratch-wound assay,” Methods in Molecular Biology, vol. 769, pp. 25–30, 2011.
- E. S. Radisky and D. C. Radisky, “Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 15, no. 2, pp. 201–212, 2010.
- C. Gialeli, A. D. Theocharis, and N. K. Karamanos, “Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting,” The FEBS Journal, vol. 278, no. 1, pp. 16–27, 2011.
- U. W. Nilsson, S. Garvin, and C. Dabrosin, “MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells,” Breast Cancer Research and Treatment, vol. 102, no. 3, pp. 253–261, 2007.
- Y. Wu and B. P. Zhou, “Snail: more than EMT,” Cell Adhesion and Migration, vol. 4, no. 2, pp. 199–203, 2010.
- M. Guarino, B. Rubino, and G. Ballabio, “The role of epithelial-mesenchymal transition in cancer pathology,” Pathology, vol. 39, no. 3, pp. 305–318, 2007.
- S. Vega, A. V. Morales, O. H. Ocaña, F. Valdés, I. Fabregat, and M. A. Nieto, “Snail blocks the cell cycle and confers resistance to cell death,” Genes and Development, vol. 18, no. 10, pp. 1131–1143, 2004.
- M. Luo and J.-L. Guan, “Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis,” Cancer Letters, vol. 289, no. 2, pp. 127–139, 2010.
- S. Hiscox, P. Barnfather, E. Hayes et al., “Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells,” Breast Cancer Research and Treatment, vol. 125, no. 3, pp. 659–669, 2011.
- S. Chia and W. Gradishar, “Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer,” Breast, vol. 17, no. 3, pp. S16–S21, 2008.
- S. Chia, W. Gradishar, L. Mauriac et al., “Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: rsults from EFECT,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1664–1670, 2008.
- A. Howell, J. F. R. Robertson, P. Abram et al., “Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1605–1613, 2004.
- N. Normanno, M. Di Maio, E. de Maio et al., “Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer,” Endocrine-Related Cancer, vol. 12, no. 4, pp. 721–747, 2005.
- S. Hiscox, L. Morgan, D. Barrow, C. Dutkowski, A. Wakeling, and R. I. Nicholson, “Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839),” Clinical and Experimental Metastasis, vol. 21, no. 3, pp. 201–212, 2004.
- N. Goto, H. Hiyoshi, I. Ito, M. Tsuchiya, Y. Nakajima, and J. Yanagisawa, “Estrogen and antiestrogens alter breast cancer invasiveness by modulating the transforming growth factor-β signaling pathway,” Cancer Science, vol. 102, no. 8, pp. 1501–1508, 2011.
- S. M. A. Abidi, E. W. Howard, J. J. Dmytryk, and J. T. Pento, “Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells,” Clinical and Experimental Metastasis, vol. 15, no. 4, pp. 432–439, 1997.
- O. Ilina, G.-J. Bakker, A. Vasaturo, R. M. Hofmann, and P. Friedl, “Two-photon laser-generated microtracks in 3D collagen lattices: Principles of MMP-dependent and -independent collective cancer cell invasion,” Physical Biology, vol. 8, no. 1, Article ID 015010, 2011.
- M. Maynadier, P. Nirdé, J.-M. Ramirez et al., “Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells,” Advances in Experimental Medicine and Biology, vol. 617, pp. 485–491, 2008.
- R. X.-D. Song, Y. Chen, Z. Zhang et al., “Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells,” Journal of Steroid Biochemistry and Molecular Biology, vol. 118, no. 4-5, pp. 219–230, 2010.
- H. Brauch and V. C. Jordan, “Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?” European Journal of Cancer, vol. 45, no. 13, pp. 2274–2283, 2009.
- D. Domínguez, B. Montserrat-Sentís, A. Virgós-Soler et al., “Phosphorylation regulates the subcellular location and activity of the snail transcriptional repressor,” Molecular and Cellular Biology, vol. 23, no. 14, pp. 5078–5089, 2003.